Research
Learn more about cutting-edge, laboratory-based basic, population, and clinical and translational-focused research publications from Massey researchers in April, May and June 2025....
Clinical
When Mary Simmons was diagnosed with acute lymphoblastic leukemia, doctors told her to she had two weeks to live. Mary Simmons got a second opinion at VCU Massey and in the darkest hour, met Keri Maher, D.O., which marked the beginning of a beautiful, atypical friendship and healing. ...
Community Engagement & Health Equity
Representatives from VCU Massey Comprehensive Cancer and the VCU School of Public Health, as well as dedicated cancer advocates and patients from Virginia, were heavily involved in this year’s Science of Community Outreach and Engagement Alliance’s second annual conference in Oakland, California. ...
Research
Said Sebti, Ph.D., associate director for basic research at Massey, is the co-inventor of PTX-100, a first-in-class small molecule inhibitor for the treatment of cutaneous T-cell lymphoma (CTCL), making Massey the first site in the United States in a global Phase 2a clinical trial evaluation. ...
Treatments in clinical trials may be more effective or have fewer side effects than the treatments that are currently available. With more than 200 studies for multiple types of cancers and cancer prevention, Massey supports a wide array of clinical trials.
Massey supports hundreds of top cancer specialists serving the needs of our patients. Massey’s medical team provides a wealth of expertise in cancer diagnosis, treatment, prevention and symptom management.
Massey is proud to partner with OncLive to provide interviews and videos from thought leaders and cutting edge articles and resources on cancer.